About Novartis
We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Access
We are committed to bringing more of our medicines to more people, no matter where they are.
People and Culture
Novartis is building an Inspired, Curious and Unbossed culture.
Latest news
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
Novartis in Society Integrated Report 2022
In 2022, we continued to reimagine medicine and deliver on our purpose to improve and extend people's lives.
Compassionate use: Providing access to much needed treatments
What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.
Environmental, Social and Governance
We have a responsibility and opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
The Novartis Commitment to Patients and Caregivers
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.